Literature DB >> 29473468

Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?

Khalil Saleh1, Nadine Khalifeh-Saleh1, Hampig Raphaël Kourie1,2.   

Abstract

Entities:  

Keywords:  PD-1/PD-L1 inhibitors; anti-PD-1; anti-PD-L1; progression; rechallenge

Mesh：

Substances：

Year:  2018        PMID： 29473468     DOI： 10.2217/imt-2017-0180

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  4 in total

1.  Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption.

Authors:  Vaia Florou; Christopher Nevala-Plagemann; Kristin E Barber; Jenna N Mastroianni; Courtney C Cavalieri; Ignacio Garrido-Laguna
Journal:  JCO Precis Oncol       Date:  2020-06-30

2.  Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature.

Authors:  Xiuju Liang; Yaping Guan; Bicheng Zhang; Jing Liang; Baocheng Wang; Yan Li; Jun Wang
Journal:  Front Oncol       Date:  2019-12-18       Impact factor: 6.244

3.  Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study.

Authors:  Junlin Yao; Xudong Zhu; Zhiheng Wu; Qing Wei; Yibo Cai; Yu Zheng; Xinyu Hu; Hong Hu; Xiangyu Zhang; Hongming Pan; Xian Zhong; Weidong Han
Journal:  Cancer Med       Date:  2022-04-10       Impact factor: 4.711

4.  Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report.

Authors:  Yiruo Zhang; Mei Zhao; Shuliang Cao; Xuchao Zhang; Yingying Du
Journal:  Thorac Cancer       Date:  2020-07-13       Impact factor: 3.500
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.